These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21985916)

  • 1. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
    Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
    Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
    Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
    J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys.
    Du Y; Tian H; Gao XD; Yao WB
    Biopharm Drug Dispos; 2008 Nov; 29(8):481-4. PubMed ID: 18985796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys.
    Enright BP; Compton DR; Collins N; Davis T; McIntyre BS
    Birth Defects Res B Dev Reprod Toxicol; 2009 Feb; 86(1):29-39. PubMed ID: 19243028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Pharmacokinetics, Tissue Distribution, Excretion of Recombinant Liver-Targeting Interferon with IFN α2b Administered Intramuscular in Rats.
    Wang J; Lu X; Jin X; Zeng W; Zhu J
    Curr Pharm Biotechnol; 2015; 16(10):911-9. PubMed ID: 26278706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
    Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of pegylated interferons: what is misleading?
    Caliceti P
    Dig Liver Dis; 2004 Nov; 36 Suppl 3():S334-9. PubMed ID: 15645663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.
    Chan LJ; Feeney OM; Leong NJ; McLeod VM; Porter CJH; Williams CC; Kaminskas LM
    Biomacromolecules; 2017 Sep; 18(9):2866-2875. PubMed ID: 28731677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.